title: Hypertension after renal transplantation.
abstract: With current immunosuppression, elevated blood pressure is found in almost 90% of renal graft recipients. Major causes of this are impairment of renal function, secondary to chronic allograft nephropathy or less frequently recurrence of primary renal disease, the use of calcineurin inhibitors as immunosuppressants, uncontrolled renin secretion by the shrunken kidneys of the recipient, stenosing lesions of the transplant artery (or the upstream arteries of the recipient), polycytemia and (genetic predisposition) to hypertension of the graft donor. Even minor degrees of blood pressure elevation have a significant impact on survival of the recipient and on graft survival, presumably by amplifying vascular injury to the graft. In this respect elevation of systolic blood pressure and an abnormal circadian blood pressure profile are of particular relevance. In contrast to previous opinion, ACE inhibitors are indicated in the treatment, but, given the causal role of sodium retention and graft vasoconstriction, diuretics and calcium channel blockers remain mainstays of antihypertensive treatment in the renal allograft recipient.
authors.affiliation: Department Internal Medicine, University of Heidelberg, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Schwenger
authors.forename: M
authors.initials: M
authors.lastname: Zeier
authors.forename: E
authors.initials: E
authors.lastname: Ritz
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D006085:Graft Survival; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D015995:Prevalence; D016019:Survival Analysis
chemical_list: D000959:Antihypertensive Agents